rs1163825 - TEX29 - LINC02337
Magnitude 4.5 · 1 study on file
Reported associations
-
A molecular pathway analysis informs the genetic risk for arrhythmias during antipsychotic treatment. - International clinical psychopharmacology (2018) · Drago A, Kure Fischer E · PubMed 29064910
Arrhythmias are a frequent and potentially fatal side effect of antipsychotic treatment. Strict ECG monitoring and clinical interviews are the standards used to prevent arrhythmias. A biologic predictive tool is missing. The identification of a genetic makeup at risk of antipsychotic-induced arrhythmias is the aim of the present investigation. The aim of this study was to identify a molecular pathway enriched in single nucleotide polymorphisms associated with antipsychotic-induced QTc modifications. In total, 661 schizophrenic individuals from the CATIE study, M=486 (73.52%), mean age=40.92±11.02, were included. QTc variation was measured as a phase-specific change-created variable. A nested mixed regression for a repeated-measures model served in R for the analysis of the clinical and tr
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
antipsychotic selection and QTc monitoring Moderate
This risk allele is associated with increased QTc interval prolongation in response to antipsychotic medications, which can cause cardiac arrhythmias.
If prescribed antipsychotics, obtain baseline and periodic ECG monitoring and discuss variant genotype with prescriber for drug selection.